Satsuma Pharmaceuticals Investor Relations Material
Latest events
Q1 2023
18 May, 2023
Q4 2022
16 Feb, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Satsuma Pharmaceuticals Inc
Access all reports
Satsuma Pharmaceuticals Inc is a development-stage biopharmaceutical company focused on innovating therapeutic products for people suffering from migraine and other debilitating conditions. Its primary product candidate is STS101, a dihydroergotamine (DHE) nasal powder, aimed at offering a significant and differentiated treatment option for acute migraine attacks. Satsuma Pharmaceuticals is headquartered in South San Francisco, California, and its shares are listed on the Nasdaq.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
STSA
Country
🇺🇸 United States